Market Overview

Bio Blast Gains 9%, Company Will Present Final Phase 2 Trial Data At Industry Conference

Related ORPN
10 Stocks Moving In Monday's Pre-Market Session
Mid-Afternoon Market Update: Infosys Rises Following Q4 Results; Ixia Shares Slide

Shares of Bio Blast Pharma Ltd (NASDAQ: ORPN) were trading higher by more than 9 percent early Friday morning after the company announced it will present final data from a Phase 2 clinical study at the American Academy of Neurology (AAN) 2016 Annual Meeting.

Bio Blast Pharma is a clinical-stage biotechnology company that focuses on the treatment of orphan diseases. The company completed a Phase 2 six-month trial of its HOPEMD therapy in patients with oculopharyngeal muscular dystrophy (OPMD).

Related Link: Update: Bio Blast Pharma Improvements Observed In Multiple Secondary Efficacy Endpoints Related To Dysphagia, Muscle Strength And Function

OPMD is a rare progressive muscle-wasting disease characterized by swallowing difficulties, leading to the risk of aspiration of food into the lungs, weight loss and muscle weakness.

The meeting will take place April 15 to 21 in Vancouver, Canada.

Posted-In: AAN American Academy of NeurologyBiotech News Events Movers Trading Ideas General


Related Articles (ORPN)

View Comments and Join the Discussion!